[1]廖 萌,淦作梅.达格列净联合二甲双胍对2型糖尿病患者尿蛋白水平及心血管不良事件的影响[J].医学信息,2024,37(13):122-125.[doi:10.3969/j.issn.1006-1959.2024.13.025]
　Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type Diabetes Mellitus.Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2024,37(13):122-125.[doi:10.3969/j.issn.1006-1959.2024.13.025]
点击复制

达格列净联合二甲双胍对2型糖尿病患者尿蛋白水平及心血管不良事件的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年13期
页码:
122-125
栏目:
论著
出版日期:
2024-07-01

文章信息/Info

Title:
Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type 2 Diabetes Mellitus
文章编号:
1006-1959（2024）13-0122-04
作者:
廖 萌; 淦作梅
（武宁县人民医院内分泌科，江西 武宁 332300）
Author(s):
Effect of Dapagliflozin Combined with Metformin on Urinary Protein Level and Cardiovascular Adverse Events in Patients with Type 2 Diabetes Mellitus
(Department of Endocrinology,People’s Hospital of Wuning County,Wuning 332300,Jiangxi,China)
关键词:
达格列净; 二甲双胍; 2型糖尿病; 尿蛋白; 心血管不良事件
Keywords:
Dapagliflozin; Metformin; Type 2 diabetes mellitus; Urinary protein; Cardiovascular adverse events
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2024.13.025
文献标志码:
A
摘要:
目的 观察达格列净联合二甲双胍对2型糖尿病患者尿蛋白水平及心血管不良事件的影响。方法 选取2020年2月-2023年2月在我院诊治的66例2型糖尿病患者为研究对象，采用随机数字表法分为对照组和观察组，各组33例。对照组采用二甲双胍治疗，观察组采用达格列净联合二甲双胍治疗，比较两组临床疗效、血糖指标、尿蛋白水平、心血管不良事件发生率及不良反应发生率。结果 观察组治疗总有效率（93.94%）高于对照组（81.82%）（P＜0.05）；两组治疗后糖化血红蛋白（HbA1c）、空腹血糖（FPG）、餐后2 h血糖（2hPG）水平均低于治疗前，且观察组低于对照组（P＜0.05）；两组治疗后尿蛋白水平均低于治疗前，且观察组低于对照组（P＜0.05）；观察组心血管不良事件发生率（9.09%）低于对照组（21.21%）（P＜0.05）；观察组不良事件发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 达格列净联合二甲双胍可提高2型糖尿病的治疗效果，降低患者尿蛋白水平，显著改善血糖指标，利于患者病情控制，还可预防心血管不良事件，且治疗安全性良好。
Abstract:
Objective To observe the effect of dapagliflozin combined with metformin on urinary protein level and cardiovascular adverse events in patients with type 2 diabetes mellitus.Methods A total of 66 patients with type 2 diabetes mellitus who were diagnosed and treated in our hospital from February 2020 to February 2023 were selected as the research objects. They were divided into control group and observation group by random number table method, with 33 patients in each group. The control group was treated with metformin, and the observation group was treated with dapagliflozin combined with metformin. The clinical efficacy, blood glucose index, urine protein level, incidence of cardiovascular adverse events and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group (93.94%) was higher than that in the control group (81.82%) (P<0.05). After treatment, the levels of glycosylated hemoglobin (HbA1c), fasting blood glucose (FPG) and 2 h postprandial blood glucose (2hPG) in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The level of urinary protein in the two groups after treatment was lower than that before treatment, and that in the observation group was lower than that in the control group (P<0.05). The incidence of cardiovascular adverse events in the observation group (9.09%) was lower than that in the control group (21.21%) (P<0.05). There was no significant difference in the incidence of adverse events between the observation group and the control group (P>0.05).Conclusion Dapagliflozin combined with metformin can improve the therapeutic effect of type 2 diabetes mellitus, reduce the level of urinary protein, significantly improve the blood glucose index, which is conducive to the control of the patient’s condition. Meanwhile, it can also prevent cardiovascular adverse events, and the treatment safety is good.

参考文献/References:

[1]卢汶,陈小燕.格列美脲联合二甲双胍或阿卡波糖治疗2型糖尿病临床对比研究[J].中南医学科学杂志,2019,47(4):404-406,410.[2]周琼兰,张敏,孙勤,等.达格列净联合二甲双胍治疗2型糖尿病合并阻塞性睡眠呼吸暂停综合征的疗效研究[J].实用医院临床杂志,2018,15(6):154-157.[3]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292-344.[4]Kim SS,Kim IJ,Lee KJ,et al.Efficacy and safety of sitagliptin/ metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study[J].J Diabetes,2018,9(4):412-422.[5]马洪川,陈华玲,朱瑞,等.达格列净联合二甲双胍治疗肥胖2型糖尿病及对血清补体、氧化应激因子和血液流变学的影响[J].临床和实验医学杂志,2021,20(12):1271-1275.[6]韩娥.达格列净对2型糖尿病胰岛素泵短期强化治疗患者胰岛素抵抗指数影响研究[J].临床军医杂志,2020,48(4):437-438.[7]李茂,罗定兰.达格列净对单用二甲双胍血糖控制不佳2型糖尿病患者的疗效及氧化应激的影响[J].临床内科杂志,2021,38(10):678-681.[8]麦华德,宋艳玲,陈明慧,等.二甲双胍联合格列美脲或达格列净对2型糖尿病患者胰岛功能及生活质量的影响[J].实用临床医药杂志,2021,25(16):61-64,69.[9]程纤,程莉,易志刚.达格列净与西格列汀治疗单用二甲双胍血糖控制不佳的2型糖尿病患者的效果的比较[J].广西医学,2020,42(24):3171-3174.[10]李晋莹,李舸.二甲双胍单药疗效不佳的2型糖尿病患者联合达格列净或格列美脲治疗的效果及安全性观察[J].海南医学,2020,31(16):2052-2055.[11]许宣波,戴武.达格列净联合二甲双胍治疗2型糖尿病的疗效及安全性分析[J].安徽医学,2021,42(1):47-50.[12]李金生,张一平,任苗苗.达格列净联合二甲双胍治疗2型糖尿病肾病的临床疗效研究[J].黑龙江医学,2020,44(7):948-950.[13]郑洁,李宏杰,马健.达格列净联合二甲双胍治疗2型糖尿病的疗效分析[J].中国处方药,2020,18(10):99-101.[14]陈晓蕾,贾农,蔡丽萍,等.达格列净联合二甲双胍治疗初诊2型糖尿病患者的临床观察[J].云南医药,2018,39(2):145-146.[15]徐明喜,耿直.达格列净片联合二甲双胍维格列汀复方制剂治疗2型糖尿病患者的临床分析[J].基层医学论坛,2021,25(10):1412-1414.[16]袁小利,王守俊.达格列净对2型糖尿病肾病患者的临床疗效[J].河南医学研究,2020,29(11):1969-1971. [17]谢瑾.达格列净联合二甲双胍治疗2型糖尿病的效果及对氧化-抗氧化平衡的影响[J].河北医药,2022,44(5):712-715.[18]Wiviott SD,Raz I,Bonaca MP,et al.Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2019,380(4):347-357. [19]赵莉,李智.达格列净干预对急性心肌梗死合并2型糖尿病患者经皮冠状动脉介入术后心室重构、心肌微灌注的影响[J].陕西医学杂志,2022,51(1):81-83,95.[20]高芳芳,张萍,钟兴,等.达格列净对血糖控制不佳的2型糖尿病患者血糖波动的影响[J].山东医药,2020,60(14):48-50.

相似文献/References:

[1]孙寿广.达格列净治疗2型糖尿病的研究进展[J].医学信息,2018,31(19):37.[doi:10.3969/j.issn.1006-1959.2018.19.013]
　SUN Shou-guang.Progress in the Study of Dapagliflozin in the Treatment of Type 2 Diabetes[J].Journal of Medical Information,2018,31(13):37.[doi:10.3969/j.issn.1006-1959.2018.19.013]
[2]刘朝阳,张善革.二甲双胍单药及不同联合用药方案治疗2型糖尿病的随机对照研究[J].医学信息,2019,32(04):148.[doi:10.3969/j.issn.1006-1959.2019.04.048]
　LIU Chao-yang,ZHANG Shan-ge.A Randomized Controlled Trial of Metformin Monotherapy and Different Combination Regimens in the Treatment of Type 2 Diabetes[J].Journal of Medical Information,2019,32(13):148.[doi:10.3969/j.issn.1006-1959.2019.04.048]
[3]苗 婷,刘子艳,刘玉媛,等.二甲双胍药理作用及其机制研究[J].医学信息,2019,32(14):53.[doi:10.3969/j.issn.1006-1959.2019.14.018]
　MIAO Ting,LIU Zi-yan,LIU Yu-yuan,et al.Study on Pharmacological Action and Mechanism of Metformin[J].Journal of Medical Information,2019,32(13):53.[doi:10.3969/j.issn.1006-1959.2019.14.018]
[4]金 川,张 颖,李瑞环,等.葛根芩连汤对2型糖尿病患者糖脂代谢指标及 体重的影响[J].医学信息,2019,32(14):164.[doi:10.3969/j.issn.1006-1959.2019.14.055]
　JIN Chuan,ZHANG Ying,LI Rui-huan,et al.Effect of Gegen Qinlian Decoction on Glucose and Lipid Metabolism Index and Body Weight in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2019,32(13):164.[doi:10.3969/j.issn.1006-1959.2019.14.055]
[5]尤 丽,卢 琦.甘精胰岛素联合二甲双胍治疗2型糖尿病的疗效[J].医学信息,2020,33(02):151.[doi:10.3969/j.issn.1006-1959.2020.02.046]
　YOU Li,LU Qi.Effect of Insulin Glargine Combined with Metformin in the Treatment of Type 2 Diabetes[J].Journal of Medical Information,2020,33(13):151.[doi:10.3969/j.issn.1006-1959.2020.02.046]
[6]董 健.达格列净治疗2型糖尿病的疗效及其对体质指数的影响[J].医学信息,2020,33(07):158.[doi:10.3969/j.issn.1006-1959.2020.07.052]
　DONG Jian.The Therapeutic Effect of Dapagliflozin on Type 2 Diabetes and Its Influence on Body Mass Index[J].Journal of Medical Information,2020,33(13):158.[doi:10.3969/j.issn.1006-1959.2020.07.052]
[7]樊小莉.达格列净治疗老年糖尿病的临床疗效及其对肾功能影响[J].医学信息,2020,33(13):158.[doi:10.3969/j.issn.1006-1959.2020.13.048]
　FAN Xiao-li.The Clinical Efficacy of Dapagliflozin in the Treatment of Senile Diabetes and Its Influence on Renal Function[J].Journal of Medical Information,2020,33(13):158.[doi:10.3969/j.issn.1006-1959.2020.13.048]
[8]王海燕,毕雪玲,曹 晶,等.坤泰胶囊联合炔雌醇环丙孕酮片、二甲双胍治疗多囊卵巢综合征的效果及对性激素的影响[J].医学信息,2020,33(20):129.[doi:10.3969/j.issn.1006-1959.2020.20.039]
　WANG Hai-yan,BI Xue-ling,CAO Jing,et al.The Effect of Kuntai Capsule Combined with Ethinyl Estradiol and Cyproterone Tablets and Metformin in the Treatment of Polycystic Ovary Syndrome and Its Influence on Sex Hormones[J].Journal of Medical Information,2020,33(13):129.[doi:10.3969/j.issn.1006-1959.2020.20.039]
[9]张月田,刘世平.二甲双胍治疗2型糖尿病的不良反应及联合用药的应用[J].医学信息,2021,34(06):64.[doi:10.3969/j.issn.1006-1959.2021.06.017]
　ZHANG Yue-tian,LIU Shi-ping.Adverse Reactions of Metformin in the Treatment of Type 2 Diabetes and the Application of Combined Medication[J].Journal of Medical Information,2021,34(13):64.[doi:10.3969/j.issn.1006-1959.2021.06.017]
[10]郑黄生,周炳凤.钠-葡萄糖协同转运蛋白-2抑制剂治疗射血分数降低心力衰竭的疗效及预后分析[J].医学信息,2021,34(10):92.[doi:10.3969/j.issn.1006-1959.2021.10.025]
　ZHENG Huang-sheng,ZHOU Bing-feng.Efficacy and Prognosis of Sodium-glucose Cotransporter-2 Inhibitor in Treatment of Heart Failure with Lower Ejection Fraction[J].Journal of Medical Information,2021,34(13):92.[doi:10.3969/j.issn.1006-1959.2021.10.025]
[11]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
　XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(13):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]

更新日期/Last Update: 1900-01-01